Dr. Bunn on Targeting HER3 in NSCLC


In Partnership With:

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Paul A. Bunn, Jr MD, distinguished professor, James Dudley Chair in Lung Cancer Research, Division of Medical Oncology, University of Colorado Denver, and a 2014 Giant of Cancer Care® in Lung Cancer, discusses potentially targeting HER3 in non–small cell lung cancer (NSCLC).

Recently, NRG1 fusions were identified as a molecular target that activates HER3, Bunn says. ​However, no agents have been approved yet to target NRG1 fusions in NSCLC.

However, the bispecific monoclonal antibody MCLA-128, that targets both HER2 and HER3, displayed promising preliminary results in patients with NSCLC, explains Bunn. 

​Currently, several agents including tarloxotinib are being evaluated for patients with NRG1 fusions and have demonstrated preclinical activity with acceptable safety profiles, Bunn concludes.

Related Videos
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center
Muhamad Alhaj Moustafa, MD, MS, hematologist, medical oncologist, Departments of Hematology and Oncology (Medical), Mayo Clinic
Reshma Jagsi, MD, DPhil, Emory University
Chandler H. Park, MD, FACP, Norton Health
Salman R. Punekar, MD, Mayo Clinic
Michael J. Overman, MD, The University of Texas MD Anderson Cancer Center,